NEUP
Neuphoria Therapeutics Inc.3.9000
+0.0700+1.83%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
20.97MP/E (TTM)
-Basic EPS (TTM)
-4.02Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
Neuphoria swung to a Q2 FY2026 net profit of $1.9M from a $1.9M loss y/y, driven by $5.4M gain on warrant liability fair value adjustments that flipped diluted EPS anti-dilutive (basic $0.41 vs -$1.23). Operating loss narrowed to $4.1M from $3.7M y/y while R&D plunged 60% post-restructuring, yet YTD operating loss widened to $9.7M from $7.3M (derived). Cash swelled to $22.2M after $17.9M ATM equity raise, funding ops beyond Q3 FY2027; no debt. Restructuring terminated nearly all staff, paused BNC210 PTSD/SAD programs amid strategic review. Cash burn halved q/q. Strategic merger hunt faces activist bids.
8-K
CEO steps to consulting role
Neuphoria Therapeutics terminated CEO Spyros Papapetropoulos' full-time employment effective December 31, 2025, triggering severance equal to one year's base salary, target bonus, and medical premiums, paid half in 2025 and the rest in 2026 installments. He stays on the board with vesting options and shifts to interim CEO consulting at $800/hour for up to 40 hours monthly, through 12 months or a strategic merger. Transition supports deal execution. No full-time replacement named.
8-K
Nasdaq compliance regained
Neuphoria Therapeutics resolved its Nasdaq compliance issue by holding its 2025 annual shareholder meeting on December 12, following a July notice for missing the deadline post fiscal year-end June 30, 2024. Nasdaq confirmed regained compliance on December 18, closing the matter. Nasdaq listing secured.
8-K
Annual meeting results out
Neuphoria Therapeutics held its annual shareholder meeting on December 12, 2025, with 39.76% turnout from 2,357,613 eligible shares. Shareholders elected Peter Miles Davies and David Wilson as Class I directors for three years, despite heavy withholding for other nominees. They ratified Wolf & Company as auditors for fiscal 2026. Say-on-pay passed; 3-year frequency won advisory vote.
10-Q
Q1 FY2026 results
Neuphoria Therapeutics posted a Q1 FY2026 operating loss of $5.7M, up 58% y/y from $3.6M, driven by R&D spend doubling to $3.8M on BNC210 PTSD ATTUNE and SAD PREVAIL trials. Net loss exploded to $9.9M or $(4.41) per share from $0.8M or $(0.62), as a $4.4M fair-value hit on accompanying warrants dwarfed $0.1M interest income—net loss exceeded operating by 76% due to those adjustments. Cash burned $3.8M in operations yet ended at $13.6M, bolstered by $3.3M ATM equity; post-quarter $15.1M more raised. Warrants expire June 2029. Strategic review follows AFFIRM-1 SAD flop. Cash lasts beyond Q2 FY2027. Nasdaq delisting looms if bid price sags.
ACAD
ACADIA Pharmaceuticals Inc.
26.80-0.46
BTAI
BioXcel Therapeutics, Inc.
1.88+0.01
EPRX
Eupraxia Pharmaceuticals Inc.
6.25+0.09
JANX
Janux Therapeutics, Inc.
14.65-0.47
NCNA
NuCana plc
3.56-0.06
NMRA
Neumora Therapeutics, Inc.
1.85-0.11
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
NXTC
NextCure, Inc.
11.12-0.35
RAPP
Rapport Therapeutics, Inc.
30.76+1.16
XENE
Xenon Pharmaceuticals Inc.
43.00-0.60